Editorial for "Betanin-Based Contrast Agents for MRI: A Preliminary Experimental Study"
- PMID: 41170764
- DOI: 10.1002/jmri.70161
Editorial for "Betanin-Based Contrast Agents for MRI: A Preliminary Experimental Study"
References
-
- T. Grobner and F. C. Prischl, “Gadolinium and Nephrogenic Systemic Fibrosis,” Kidney International 72, no. 3 (2007): 260–264, https://doi.org/10.1038/sj.ki.5002338.
-
- T. Kanda, K. Ishii, H. Kawaguchi, K. Kitajima, and D. Takenaka, “High Signal Intensity in the Dentate Nucleus and Globus Pallidus on Unenhanced T1‐Weighted MR Images: Relationship With Increasing Cumulative Dose of a Gadolinium‐Based Contrast Material,” Radiology 270, no. 3 (2014): 834–841, https://doi.org/10.1148/radiol.13131669.
-
- A. G. Rockall, B. Allen, M. J. Brown, et al., “Sustainability in Radiology: Position Paper and Call to Action From ACR, AOSR, ASR, CAR, CIR, ESR, ESRNM, ISR, IS3R, RANZCR, and RSNA,” Radiology 314, no. 3 (2025): e250325, https://doi.org/10.1148/radiol.250325.
-
- C. Robic, M. Port, O. Rousseaux, et al., “Physicochemical and Pharmacokinetic Profiles of Gadopiclenol: A New Macrocyclic Gadolinium Chelate With High T1 Relaxivity,” Investigative Radiology 54, no. 8 (2019): 475–484, https://doi.org/10.1097/RLI.0000000000000563.
-
- S. Roy, J. Gu, W. Xia, C. Mi, and B. Guo, “Advancements in Manganese Complex‐Based MRI Agents: Innovations, Design Strategies, and Future Directions,” Drug Discovery Today 29, no. 9 (2024): 104101, https://doi.org/10.1016/j.drudis.2024.104101.
Publication types
LinkOut - more resources
Full Text Sources
